WorldWide Chemical Analyzers Market, Industry / Sector Analysis Report, Regional Outlook & Competitive Market Share & Forecast, 2019 - 2025 (Includes Business Impact of COVID-19)

                                          
Chemical Analyzers Market size is set to witness healthy gains in the coming years. Growing geriatric population across the globe will be the high impact rendering factor for the chemical analyzers market.
 

Geriatric population (aged 65 and older) forms 7% of the total world population. In Japan, about 33% of the population was aged over 60, while in Germany and Italy, about 28% of the population was over 60 as of 2015. These elderly patients are prone to lifestyle diseases, such as heart-related diseases, and requires regular medical checkup.
 

Growing incidences and prevalence of lifestyle diseases are predicted to drive the market over the forecast period. Lifestyle diseases, such as heart disease and diabetes, are the leading causes of death and disability across the globe. Chemical analyzers reduce the burden of such diseases by providing early and accurate diagnosis. Chemical analyzers further help in understanding the causal factors and disease function, which enables the prevention of diseases.
 

The launch of technologically advanced products in the market has improved user convenience. Time and cost-effective instruments are being launched in the market with high-throughput and increased analytical range. For instance, Roche launched cobas c 513 analyzer, to address the growing demand for HbA1c testing of patients with diabetes. The newly launched analyzer minimizes the risk by providing accurate results in lesser time.
 

However, the high cost associated with chemical analyzers is predicted to impede the industry growth over the forecast period.
 

Chemical analyzers are used to detect the concentration of electrolyte, lipid, cholesterol, glucose, calcium, carbohydrate, protein, and other molecules in bodily fluids, such as blood, plasma, urine, and serum. The analyzers aid in the diagnosis and treatment of a wide range of diseases including heart diseases, hepatitis, cancer, diabetes, thyroid problems, HIV, and STD.
 

Chemical analyzer instruments include various automated and semi-automated instruments that perform the analysis of biological fluids such as blood, serum, saliva, and urine. These instruments vary in size and capability of performing number of tests per hour. A biological sample is mixed with different reagents prior to loading in analyzer. Reagents chemically react with the components to be analyzed and produces color. The instrument measures the intensity or wavelength absorbed by the color to determine the concentration of target elements.
 

Chemistry panels include tests that are performed to determine the health status of patients. Different chemistry panels consist of Basic Metabolic Panel, Comprehensive Metabolic Panel, Comprehensive Metabolic Panel, Electrolyte Panel, Liver Panel, Renal Panel, and Thyroid Function Panel.
 

Basic metabolic panel is expected to dominate the market due to the high prevalence of metabolic abnormalities and lifestyle diseases. In this test, patient’s blood is analyzed to measure quantitatively the presence of glucose, electrolyte, and kidney functions. It also enables monitoring the effects of administered drugs, such as diuretics.
 

Similarly, liver panel is a test performed to determine the presence of liver inflammation, liver infection, and other liver-related diseases and lipid profile test is used to assess the risk of developing cardiovascular diseases.
 

Hospitals are using chemical analyzers for diagnosis diseases, such as heart disease, diabetes, and HIV. Growing incidences and prevalence of such diseases is expected to escalate the use of chemical analyzers by hospitals. Further, hospitals are preferring high-throughput automated analyzers that reduce the time required to perform the analysis and provide accurate results with minimum cost.
 

The U.S. witnessed a significant rise in the geriatric population and prevalence of lifestyle diseases, such as cancer, heart disease, and diabetes. Moreover, this prevalence is expected to grow further. For instance, 29.1 million people in the U.S were diagnosed with diabetes in 2014. Demand for chemical analyzers is predicted to remain high owing to the need for the early detection of such diseases.
 

APAC exhibits a high prevalence of lifestyle diseases driving the regional market growth. For instance, annually over 5.8 million deaths occurred in India from heart and lung diseases, stroke, cancer, and diabetes.
 

Some of the key industry players operating in chemical analyzers market include Danaher Corporation, Mindray Medical International, Thermo Fisher Scientific, Abbott Laboratories, Johnson & Johnson, Siemens, F.Hoffmann-La Roche, Elitech, Carolina Liquid Chemistries, Randox Laboratories, and Nova Biomedical.